Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

19S Proteasome Subunits As Oncogenes and Prognostic Biomarkers in FLT3-Mutated Acute Myeloid Leukemia (AML)

Joshua J. Lara, Alfonso E. Bencomo, Mayra A. Gonzalez, Idaly M. Olivas, Jose L. Lopez, James E. Young, Vanessa V. Velazquez, Steven Glovier, Andres J. Rubio, Sara K. Dang, Jonathan Solecki, Jesse Allen, Desiree N. Tapia, Boranai Tychhon, Gonzalo E. Astudillo, Darshan S. Chandrashekar, Anna M. Eiring

Blood (2022) 140 (Supplement 1): 3381–3382.

https://doi.org/10.1182/blood-2022-162818

Published: 2022

Journal Articles

Unexpected myeloid sarcoma of the tonsil in a patient without a history of hematological neoplasm

Paul E. Young, L. Jeffrey Medeiros

Blood (2022) 139 (1): 148.

https://doi.org/10.1182/blood.2021013394

Published: 2022

Journal Articles

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Afoluso Ronnee Adesanya, MD, Patrick S. Zbyszewski, MBA, Richard C. Woodman, MD, Pierre Fenaux, MD PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 566.

https://doi.org/10.1182/blood-2019-131676

Published: 2019

Journal Articles

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Maro N. Ohanian, DO, Rosmy B. John, MSN, Patrick S. Zbyszewski, MBA, Manoj Maniar, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 230.

https://doi.org/10.1182/blood-2018-99-119259

Published: 2018

Journal Articles

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting

Blood (2016) 127 (24): 3004–3014.

https://doi.org/10.1182/blood-2015-08-664649

Published: 2016

Includes: Supplemental data

Journal Articles

Clinical Utility of Comprehensive Profiling of Genomic Alterations in Hematologic Malignancies

Blood (2014) 124 (21): 1072.

https://doi.org/10.1182/blood.V124.21.1072.1072

Published: 2014

Journal Articles

PAI at breakfast (whether you like it or not)

Martin E. Young

Blood (2014) 123 (4): 466–468.

https://doi.org/10.1182/blood-2013-11-538330

Published: 2014

Journal Articles

Integrated Genetic Profiling Of JAK2 Wildtype Chronic-Phase Myeloproliferative Neoplasms

Raajit K. Rampal, M.D., Ph.D., Sean M. Devlin, PhD, Jay P. Patel, Kristina M. Knapp, BS, Minal Patel, Joel R Greenbowe, BS, Lauren E Young, MS, Jie He, PhD, Kai Wang, MD PhD, Michelle K. Nahas, PhD, Roman Yelensky, PhD, Geoff A. Otto, PhD, Doron Lipson, PhD, Philip J. Stephens, PhD, Vincent A. Miller, MD, Ross L. Levine, MD

Blood (2013) 122 (21): 1588.

https://doi.org/10.1182/blood.V122.21.1588.1588

Published: 2013

Journal Articles

Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay

Blood (2013) 122 (21): 230.

https://doi.org/10.1182/blood.V122.21.230.230

Published: 2013

Journal Articles

Coagulation Cofactor Presentation and Complex Assembly on Platelets by Protease Activated Receptors (PARs): PAR4 Stimulation Leads to More FV and FVIII and More Thrombin Generation Than PAR1

Matthew T Duvernay, PhD, Summer E Young, BS, David Gailani, MD, Jonathan G Schoenecker, MD PhD, Heidi Hamm, PhD

Blood (2011) 118 (21): 1135.

https://doi.org/10.1182/blood.V118.21.1135.1135

Published: 2011

Journal Articles

Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo

JM Muir, M Andrew, J Hirsh, JI Weitz, E Young, P Deschamps, SG Shaughnessy

Blood (1996) 88 (4): 1314–1320.

https://doi.org/10.1182/blood.V88.4.1314.bloodjournal8841314

Published: 1996

Journal Articles

The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria

SG Shaughnessy, E Young, P Deschamps, J Hirsh

Blood (1995) 86 (4): 1368–1373.

https://doi.org/10.1182/blood.V86.4.1368.bloodjournal8641368

Published: 1995

Journal Articles

Brief Report: The Isolation of Cytomegalovirus from Peripheral Blood

D. G. HARNDEN, B.Sc., PH.D., T. R. ELSDALE, B.Sc., PH.D., D. E. YOUNG, B.Sc., PH.D., A. ROSS, FIMLT

Blood (1967) 30 (1): 120–125.

https://doi.org/10.1182/blood.V30.1.120.120

Published: 1967

Journal Articles

Studies on Spontaneous In Vitro Autohemolysis in Hemolytic Disorders

LAWRENCE E. YOUNG, MARY JANE IZZO, KURT I. ALTMAN, SCOTT N. SWISHER

Blood (1956) 11 (11): 977–997.

https://doi.org/10.1182/blood.V11.11.977.977

Published: 1956

Journal Articles

Panels in Therapy: V. The Use of Cobalt and Cobalt-Iron Preparations in the Therapy of Anemia

LAWRENCE BERMAN, GEORGE E. CARTWRIGHT, C. LOCKARD CONLEY, WILLIAM H. CROSBY, CLEMENT A. FINCH, ROBERT W. HEINLE, LEON O. JACOBSON, JOHN S. LAWRENCE, CARL V. MOORE, JOSEPH F. ROSS, WAYNE RUNDLES, WALLACE JENSEN, L. M. TOCANTINS, RICHARD W. VILTER, M. M. WINTROBE, LAWRENCE E. YOUNG, W. W. ZUELZER

Blood (1955) 10 (8): 852–861.

https://doi.org/10.1182/blood.V10.8.852.852

Published: 1955

Journal Articles

Hereditary Spherocytosis : II. Observations on the Role of the Spleen

LAWRENCE E. YOUNG, M.D., RICHARD F. PLATZER, M.D., DONALD M. ERVIN, M.D., MARY JANE IZZO, M.S.

Blood (1951) 6 (11): 1099–1113.

https://doi.org/10.1182/blood.V6.11.1099.1099

Published: 1951

Journal Articles

Hereditary Spherocytosis : I. Clinical, Hematologic and Genetic Features in 28 Cases, with Particular Reference to the Osmotic and Mechanical Fragility of Incubated Erythrocytes

LAWRENCE E. YOUNG, M.D., MARY JANE IZZO, M.S., RICHARD F. PLATZER, M.D.

Blood (1951) 6 (11): 1073–1098.

https://doi.org/10.1182/blood.V6.11.1073.1073

Published: 1951

Journal Articles

Hemolytic Disease in Newborn Dogs

LAWRENCE E. YOUNG, RICHARD M. CHRISTIAN, DONALD M. ERVIN, R. WENDELL DAVIS, WILLIAM A. O’BRIEN, SCOTT N. SWISHER, CHARLES L. YUILE, Mary Jane Izzo, Jane Hogestyn Peters

Blood (1951) 6 (6): 584.

https://doi.org/10.1182/blood.V6.6.584.584

Published: 1951

Journal Articles

Hemolytic Disease in Newborn Dogs

LAWRENCE E. YOUNG, M.D., RICHARD M. CHRISTIAN, M.D., DONALD M. ERVIN, M.D., R. WENDELL DAVIS, M.D., WILLIAM A. O’BRIEN, M.D., SCOTT N. SWISHER, M.D., CHARLES L. YUILE, M.D., Mary Jane Izzo, M.S., Jane Hogestyn Peters, B.A.

Blood (1951) 6 (4): 291–313.

https://doi.org/10.1182/blood.V6.4.291.291

Published: 1951

Journal Articles

Limitation of Hemolysis in Experimental Transfusion Reactions Related to Depletion of Complement and Isoantibody in the Recipient : Observations on Dogs Given Successive Transfusions of Incompatible Red Cells Tagged with Radioactive Iron

R. M. CHRISTIAN, M.D., W. B. STEWART, M.D., C. L. YUILE, M.D., D. M. ERVIN, M.D., L. E. YOUNG, M.D.

Blood (1951) 6 (2): 142–150.

https://doi.org/10.1182/blood.V6.2.142.142

Published: 1951

NARROW

19S Proteasome Subunits As Oncogenes and Prognostic Biomarkers in FLT3-Mutated Acute Myeloid Leukemia (AML)

Unexpected myeloid sarcoma of the tonsil in a patient without a history of hematological neoplasm

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting

Clinical Utility of Comprehensive Profiling of Genomic Alterations in Hematologic Malignancies

PAI at breakfast (whether you like it or not)

Integrated Genetic Profiling Of JAK2 Wildtype Chronic-Phase Myeloproliferative Neoplasms

Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay

Coagulation Cofactor Presentation and Complex Assembly on Platelets by Protease Activated Receptors (PARs): PAR4 Stimulation Leads to More FV and FVIII and More Thrombin Generation Than PAR1

Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo

The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria

Brief Report: The Isolation of Cytomegalovirus from Peripheral Blood

Studies on Spontaneous In Vitro Autohemolysis in Hemolytic Disorders

Panels in Therapy: V. The Use of Cobalt and Cobalt-Iron Preparations in the Therapy of Anemia

Hereditary Spherocytosis : II. Observations on the Role of the Spleen

Hereditary Spherocytosis : I. Clinical, Hematologic and Genetic Features in 28 Cases, with Particular Reference to the Osmotic and Mechanical Fragility of Incubated Erythrocytes

Hemolytic Disease in Newborn Dogs

Hemolytic Disease in Newborn Dogs

Limitation of Hemolysis in Experimental Transfusion Reactions Related to Depletion of Complement and Isoantibody in the Recipient : Observations on Dogs Given Successive Transfusions of Incompatible Red Cells Tagged with Radioactive Iron

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only